Design of treatment trials for functional gastrointestinal disorders

Gastroenterology

Volumn 150, Issue 6, 2016, Pages 1469-1480.e1

  Irvine, E Jan ^a,b   Tack, Jan ^c   Crowell, Michael D ^d   Gwee, Kok Ann ^e   Ke, Meiyun ^f   Schmulson, Max J ^g   Whitehead, William E ^h   Spiegel, Brennan ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d MAYO CLINIC   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^g UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Controlled Trial; Functional Gastrointestinal Disorders; Intention to Treat; Patient Reported Outcome Measure

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; BLOATING; CALCULATION; COMORBIDITY; DEFECATION URGENCY; DIET; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ACTIVITY; FECES; FOOD AND DRUG ADMINISTRATION; HUMAN; INTENTION TO TREAT ANALYSIS; IRRITABLE COLON; NOCEBO EFFECT; PATIENT COMPLIANCE; PLACEBO EFFECT; PRACTICE GUIDELINE; PRECEBO EFFECT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; TREATMENT DURATION; GASTROINTESTINAL DISEASES; METHODOLOGY;

GASTROINTESTINAL DISEASES; RESEARCH DESIGN;

EID: 84964797315     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.02.010     Document Type: Article

References (87)

1. M. Corsetti, and J. Tack FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 25 2013 453 457
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf. Published May 2012. Accessed January 10, 2015.
3. European Medicines Agency Guideline on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome. Vol 2014 2013 EMA London, UK
4. G. Holtmann, S.U. Kutscher, S. Haag, and et al. Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study Dig Dis Sci 49 2004 672 679
5. R.C. Spiller Potential biomarkers Gastroenterol Clin N Am 40 2011 121 139
6. R.C. Spiller Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials Am J Med 107 1999 91S 97S
7. O.S. Palsson, J. Baggish, and W.E. Whitehead Episodic nature of symptoms in irritable bowel syndrome Am J Gastroenterol 109 2014 1450 1460
8. D.A. Drossman, and W.G. Thompson The irritable bowel syndrome: review and a graduated multicomponent treatment approach Ann Intern Med 116 1992 1009 1016
9. W.E. Whitehead Control groups appropriate for behavioral interventions Gastroenterology 126 Suppl 1 2004 S159 S163
10. M. Camilleri Safety concerns about alosetron Arch Intern Med 162 2002 100 101
11. D.L. Sackett Bias in analytic research J Chronic Dis 32 1979 51 63
12. F. Jamshidian, A.E. Hubbard, and N.P. Jewell Accounting for perception, placebo and unmasking effects in estimating treatment effects in randomised clinical trials Stat Methods Med Res 23 2011 293 307
13. B. Spilker External influences on protocol design Epilepsy Res Suppl 10 1993 115 124
14. G.J. Devilly, and T.D. Borkovec Psychometric properties of the credibility/expectancy questionnaire J Behav Ther Exp Psychiatry 31 2000 73 86
15. D.G. Altman Randomisation BMJ 302 1991 1481 1482
16. D.G. Altman Comparability of randomised groups Statistician 1985 125 136
17. J.M. Tinmouth, L.S. Steele, G. Tomlinson, and et al. Are claims of equivalency in digestive diseases trials supported by the evidence? Gastroenterology 126 2004 1700 1710
18. R.J. Temple When are clinical trials of a given agent vs. Placebo no longer appropriate or feasible? Control Clin Trials 18 1997 613 620 discussion 661-666
19. W.G. Thompson Placebos: a review of the placebo response Am J Gastroenterol 95 2000 1637 1643
20. C.N. Bernstein Placebos in medicine Semin Gastrointest Dis 10 1999 3 7
21. S.J. Veldhuyzen van Zanten, C. Cleary, N.J. Talley, and et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials Am J Gastroenterol 91 1996 660 673
22. F. Musial, S. Klosterhalfen, and P. Enck Placebo responses in patients with gastrointestinal disorders World J Gastroenterol 13 2007 3425 3429
23. L. Vase, M.E. Robinson, G.N. Verne, and et al. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation Pain 105 2003 17 25
24. M. Pitz, M. Cheang, and C.N. Bernstein Defining the predictors of the placebo response in irritable bowel syndrome Clin Gastroenterol Hepatol 3 2005 237 247
25. A.C. Ford, and P. Moayyedi Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome Aliment Pharmacol Ther 32 2010 144 158
26. S.E. Kim, S. Kubomoto, K. Chua, and et al. "Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials J Clin Gastroenterol 46 2012 686 690
27. V.W. Berger, A. Rezvani, and V.A. Makarewicz Direct effect on validity of response run-in selection in clinical trials Control Clin Trials 24 2003 156 166
28. D.A. Drossman, M. Camilleri, E.A. Mayer, and et al. AGA technical review on irritable bowel syndrome Gastroenterology 123 2002 2108 2131
29. D. Silvers, M. Kipnes, V. Broadstone, and et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group Clin Ther 20 1998 438 453
30. S. Heymen, Y. Scarlett, K. Jones, and et al. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence Dis Colon Rectum 52 2009 1730 1737
31. S.S. Rao, K. Seaton, M. Miller, and et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation Clin Gastroenterol Hepatol 5 2007 331 338
32. W.D. Chey, A.J. Lembo, B.J. Lavins, and et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Am J Gastroenterol 107 2012 1702 1712
33. P. Ducrotte, J.C. Grimaud, M. Dapoigny, and et al. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study Int J Clin Pract 68 2014 245 254
34. A.A. Stone, and S. Shiffman Capturing momentary, self-report data: a proposal for reporting guidelines Ann Behav Med 24 2002 236 243
35. C.K. Yao, P.R. Gibson, and S.J. Shepherd Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders Am J Gastroenterol 108 2013 748 758
36. E.P. Halmos, V.A. Power, S.J. Shepherd, and et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome Gastroenterology 146 2014 67 75 e5
37. A. Passariello, P. Agricole, and P. Malfertheiner A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases Curr Med Res Opin 30 2014 1055 1064
38. D. Haller, J.M. Antoine, S. Bengmark, and et al. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome J Nutr 140 2010 690S 697S
39. S.R. Tunis, D.B. Stryer, and C.M. Clancy Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 2003 1624 1632
40. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry. Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Published December 2009. Accessed January 10, 2015.
41. L.B. Burke, D.L. Kennedy, P.H. Miskala, and et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval Clin Pharmacol Ther 84 2008 281 283
42. B.B. Reeve, R.D. Hays, J.B. Bjorner, and et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS) Med Care 45 Suppl 1 2007 S22 S31
43. B. Spiegel, R. Bolus, N. Agarwal, and et al. Measuring symptoms in irritable bowel syndrome: development of a framework for clinical trials Aliment Pharmacol Ther 32 2010 1192 1202
44. B.B. Dean, D. Aguilar, V. Barghout, and et al. Impairment in work productivity and health-related quality of life in patients with IBS Am J Manag Care 11 Suppl 2005 S17 S26
45. B. Spiegel, L. Harris, S. Lucak, and et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort Am J Gastroenterol 104 2009 1984 1991
46. M. Camilleri, A.W. Mangel, S.E. Fehnel, and et al. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints Clin Gastroenterol Hepatol 5 2007 534 540
47. C.J. Bijkerk, N.J. de Wit, J.W. Muris, and et al. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics Am J Gastroenterol 98 2003 122 127
48. A.W. Mangel, B.A. Hahn, A.T. Heath, and et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome J Int Med Res 26 1998 76 81
49. B. Spiegel, M. Camilleri, R. Bolus, and et al. Psychometric evaluation of patient reported outcomes in IBS randomized controlled trials: a Rome Foundation report Gastroenterology 137 2009 1944 1953 e1-e3
50. C.Y. Francis, J. Morris, and P.J. Whorwell The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress Aliment Pharmacol Ther 11 1997 395 402
51. D.A. Drossman, Z. Li, B.B. Toner, and et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index Dig Dis Sci 40 1995 986 995
52. D. Ang, N.J. Talley, M. Simren, and et al. Review article: endpoints used in functional dyspepsia drug therapy trials Aliment Pharmacol Ther 33 2011 634 649
53. L.E. Mansoor, and R. Dowse Effect of pictograms on readability of patient information materials Ann Pharmacother 37 2003 1003 1009
54. J. Tack, F. Carbone, L. Holvoet, and et al. The use of pictograms improves symptom evaluation by patients with functional dyspepsia Aliment Pharmacol Ther 40 2014 523 530
55. B.M. Spiegel, I.M. Gralnek, R. Bolus, and et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome Arch Intern Med 164 2004 1773 1780
56. R.S. Sandler, W.F. Stewart, J.N. Liberman, and et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact Digest Dis Sci 45 2000 1166 1171
57. S.J. Lewis, and K.W. Heaton Stool form scale as a useful guide to intestinal transit time Scand J Gastroenterol 32 1997 920 924
58. A.E. Bharucha, A.R. Zinsmeister, G.R. Locke, and et al. Risk factors for fecal incontinence: a population-based study in women Am J Gastroenterol 101 2006 1305 1312
59. G.H. Guyatt, D.H. Feeny, and D.L. Patrick Measuring health-related quality of life Ann Intern Med 118 1993 622 629
60. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
61. M. Bergner, R.A. Bobbitt, W.B. Carter, and et al. The Sickness Impact Profile: development and final revision of a health status measure Med Care 19 1981 787 805
62. P. Khanna, N. Agarwal, D. Khanna, and et al. Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO Database Am J Gastroenterol 109 2014 234 248
63. D.L. Patrick, D.A. Drossman, I.O. Frederick, and et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure Diges Dis Sci 43 1998 400 411
64. A. Koop, and R. Mosges The use of handheld computers in clinical trials Control Clin Trials 23 2002 469 480
65. A.A. Stone, S. Shiffman, J.E. Schwartz, and et al. Patient compliance with paper and electronic diaries Control Clin Trials 24 2003 182 199
66. C. Begg, M. Cho, S. Eastwood, and et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement JAMA 276 1996 637 639
67. D. Moher, K.F. Schulz, and D. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials JAMA 285 2001 1987 1991
68. K.F. Schulz, D.G. Altman, and D. Moher CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials Ann Intern Med 152 2010 726 732
69. T.V. Perneger What's wrong with Bonferroni adjustments BMJ 316 1998 1236 1238
70. G. Guyatt, R. Jaeschke, N. Heddle, and et al. Basic statistics for clinicians: 2. Interpreting study results: confidence intervals CMAJ 152 1995 169 173
71. J. Nuovo, J. Melnikow, and D. Chang Reporting number needed to treat and absolute risk reduction in randomized controlled trials JAMA 287 2002 2813 2814
72. S.M. Gore, G. Jones, and S.G. Thompson The Lancet's statistical review process: areas for improvement by authors Lancet 340 1992 100 102
73. M.H. Katz Multivariable analysis: a primer for readers of medical research Ann Intern Med 138 2003 644 650
74. A.D. Oxman, and G.H. Guyatt A consumer's guide to subgroup analyses Ann Intern Med 116 1992 78 84
75. D.G. Smith, J. Clemens, W. Crede, and et al. Impact of multiple comparisons in randomized clinical trials Am J Med 83 1987 545 550
76. S.F. Assmann, S.J. Pocock, L.E. Enos, and et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials Lancet 355 2000 1064 1069
77. J.P. Ioannidis, S.J. Evans, P.C. Gotzsche, and et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement Ann Intern Med 141 2004 781 788
78. M.J. Campbell, S.A. Julious, and D.G. Altman Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons BMJ 311 1995 1145 1148
79. A.S. Detsky, and D.L. Sackett When was a "negative" clinical trial big enough? How many patients you needed depends on what you found Archives of internal medicine 145 1985 709 712
80. R.W. Makuch, and M.F. Johnson Some issues in the design and interpretation of 'negative' clinical studies Arch Intern Med 146 1986 986 989
81. D.A. Berry Interim analyses in clinical trials: classical vs. Bayesian approaches Stat Med 4 1985 521 526
82. N.L. Geller, and S.J. Pocock Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners Biometrics 43 1987 213 223
83. S.C. Chow Adaptive clinical trial design Annu Rev Med 65 2014 405 415
84. S.J. Pocock When to stop a clinical trial BMJ 305 1992 235 240
85. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics. Available at: http://www.fda.gov/downloads/Drugs/./Guidances/UCM201790.pdf. Published February 2010. Accessed January 10, 2015.
86. S.J. Pocock The pros and cons of noninferiority trials Fundam Clin Pharmacol 17 2003 483 490
87. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry Non-Inferiority Clinical Trials. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf. Published March 2010. Accessed January 10, 2015.